Classification of KIT/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy.

Expert Rev Anticancer Ther 2015 Jun 1;15(6):623-8. Epub 2015 Apr 1.

Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Building D17, Albert-Schweitzer-Campus 1, Münster 48149, Germany.

Gastrointestinal stromal tumors (GIST) are driven mostly by oncogenic KIT or PDGFRA mutations. However, in 10-15% of all GIST, no such activating mutations can be found and these tumors are classified as 'wild-type GIST' (KIT/PDGFRA wt-GIST). Subgroups of KIT/PDGFRA wt-GIST are driven by other sporadic mutations involving the RAS/RAF/MAP-kinase pathway, such as BRAF or KRAS mutations. Furthermore, KIT/PDGFRA wt-GIST are observed in the context of hereditary syndromes, such as neurofibromatosis Type 1, in which the lack of neurofibromin 1 also leads to the activation of the RAS/RAF/MAP-kinase pathway. Finally, the deficiency succinate dehydrogenase seems to play a major role in KIT/PDGFRA wt-GIST. In conclusion, KIT/PDGFRA wt-GIST belong to different subgroups defined by diverse underlying genetic alterations leading to different biological phenotypes. The vast majority of KIT/PDGFRA wt-GIST will not respond to imatinib. Further research to unravel the pathogenesis of KIT/PDGFRA wt-GIST is prerequisite to the development of effective treatment strategies.

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.2015.1032941DOI Listing
June 2015
17 Reads

Publication Analysis

Top Keywords

kit/pdgfra wt-gist
28
ras/raf/map-kinase pathway
8
stromal tumors
8
gastrointestinal stromal
8
wt-gist
7
kit/pdgfra
7
wt-gist will
4
hereditary syndromes
4
context hereditary
4
will respond
4
syndromes neurofibromatosis
4
neurofibromatosis type
4
vast majority
4
type lack
4
majority kit/pdgfra
4
observed context
4
wt-gist observed
4
diverse underlying
4
imatinib unravel
4
pathway braf
4

Similar Publications